The study’s authors did not measure whether individuals seeking testing were vaccinated against COVID-19. Daniel Harris, who joined UD’s epidemiology program faculty this fall, gained rare access to ...

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights. Read why I am bullish about WGS stock.

GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.

Patients and doctors need to have access to them and patient privacy must be protected at the same time, the author writes.

Post this Blood-based Nodify Lung testing, comprised of the Nodify CDT® and Nodify XL2® tests, addresses a significant unmet need by assessing the risk of cancer in patients with lung nodules.

The Patient Access Program aims to address these challenges by increasing access to whole exome sequencing for pediatric epilepsy patients.